Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine
California
92618
United States
Tel: 949-788-6700
Fax: 949-788-6706
Website: http://www.spectrumpharm.com/
Email: info@spectrumpharm.com
616 articles about Spectrum Pharmaceuticals, Inc.
-
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
7/20/2023
Spectrum Pharmaceuticals, Inc. have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Special Meeting”) on July 27, 2023.
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
3/22/2023
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period and full year ended December 31, 2022.
-
Spectrum Pharmaceuticals Announces Management Changes
1/4/2023
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately.
-
Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATE
11/25/2022
Kaplan Fox & Kilsheimer LLP is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities.
-
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
11/3/2022
Spectrum Pharmaceuticals, Inc. today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022, at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
12/1/2021
Spectrum Pharmaceuticals, Inc. announced today that Tom Riga, currently Chief Commercial and Chief Operating Officer, will be the next President and CEO effective December 31, 2021.
-
Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update
11/10/2021
Spectrum Pharmaceuticals, Inc. today announced financial results for the three-month period ended September 30, 2021 and provided a corporate update.
-
Spectrum Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Corporate Update
10/28/2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate update on Wednesday, November 4, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Wednesday, November 4, 2020 @ 4:30 p.m. Eastern/1:30 p.m. P
-
Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim)
10/26/2020
Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions
-
"We are actively working with the FDA to find a way to expedite the plant inspection," said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals. "The manufacturing facility is ready for inspection and we are eager to assist the FDA in completing their assessment as soon as possible."
-
The U.S. Food and Drug Administration has several PDUFA dates for the rest of October, although two of them were already approved. Here’s a look.
-
Spectrum Pharmaceuticals Presents Results in HER2 Exon 20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Clinical Trial
9/18/2020
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.
-
Spectrum Pharmaceuticals Announces Two Presentations for Poziotinib at ESMO Virtual Congress 2020
9/14/2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. In addition, a poster presentation of results from a single site expanded
-
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September 2020
9/8/2020
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences
-
Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update
8/10/2020
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2020.
-
Spectrum Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
8/5/2020
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the underwriters of its previously announced public offering of common stock have fully exercised and closed on their option to purchase an additional 3,250,000 shares of the Company’s common stock at the public offering price of $3.00 per share, less underwriting discounts and commissions,
-
Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update
8/3/2020
Spectrum Pharmaceuticals a biopharmaceutical company focused on novel and targeted oncology therapies, announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate update on Monday, August 10, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Spectrum Pharmaceuticals Announces Pricing of Public Offering of Common Stock - July 30, 2020
7/30/2020
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the pricing of an underwritten public offering of 21,666,667 shares of its common stock at a public offering price of $3.00 per share.
-
Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock
7/29/2020
Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering
-
Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial
7/27/2020
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it met the pre-specified primary endpoint in the ZENITH20 Phase 2 clinical trial evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2).